Abstracts tagged "Disease Activity"

Abstract Number: 1597 • ACR Convergence 2020
Use of a Clinical Dashboard Improves the Documentation of Disease Severity Scores and May Facilitate the Implementation of Treat to Target Therapy
Taylor Nelson¹, Gary Kunkel² and Grant Cannon², ¹University of Utah, Salt Lake City, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City
Background/Purpose: Rheumatoid Arthritis (RA) management guidelines recommend the collection of Disease Activity Measures (DAMs) to direct therapy as a component of a “treat-to-target” (T2T) strategy. …
Abstract Number: 1760 • ACR Convergence 2020
The Association Between the Risk of Venous Thromboembolism and Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Observational Study
Masaru Yoshimura¹, Yuichiro Fujieda², Michihito Kono², Masaru Kato², Kenji Oku², Olga Amengual² and Tatsuya Atsumi³, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan
Background/Purpose: Rheumatoid arthritis (RA) is an immune-mediated synovial disease with chronic inflammation. Systemic inflammation is considered one of risk factors for venous thromboembolism (VTE), which…
Abstract Number: 1887 • ACR Convergence 2020
Spinal Mobility and Function: How Closely Do They Associate in Axial Spondyloarthropathy?
Sinead Maguire¹, Phil Gallagher² and Finbar O'Shea¹, ¹St James' Hospital, Dublin, Ireland, ²St Vincents University Hospital, UCD, Dublin, Ireland
Background/Purpose: Axial spondyloarthropathy (axSpA) is a form of inflammatory arthritis affecting the axial skeleton. Persistent disease activity can result in restricted spinal mobility over time,…
Abstract Number: 033 • 2020 Pediatric Rheumatology Symposium
Parental Adverse Childhood Experience (ACE) Exposure Is Predictive of Active Lupus in Pediatric Patients
Michael Nelson¹, Nancy Correa ², Ashley Butler ¹, Marietta De Guzman ³, Bethanie Van Horne ¹ and Christopher Greeley ¹, ¹Baylor College of Medicine, Houston, ²Texas Children's Hospital, Houston, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
Background/Purpose: Adverse Childhood Experiences (ACEs) have been recognized for more than two decades as risk factors for poor health outcomes in adults. Nevertheless, the impact…
Abstract Number: 071 • 2020 Pediatric Rheumatology Symposium
Patient Reported Outcomes and Resilience in Pediatric Systemic Lupus Erythematosus
Lauren Ambler¹, Rula Issa ², Stephanie Pan ² and Rebecca Trachtman ², ¹Mount Sinai Hospital, New York, ²Icahn School of Medicine at Mount Sinai, New York
Background/Purpose: It has been established that pediatric Systemic Lupus Erythematous (pSLE) is associated with lower health-related quality of life (HRQOL); however, there are few studies…
Abstract Number: 078 • 2020 Pediatric Rheumatology Symposium
Reliability and Validity of a New Skin Activity Measure for Localized Scleroderma
Suzanne Li¹, Mara Becker ², Sandy Hong ³, Polly Ferguson ⁴, Themba Nyrienda ⁵, Tracy Andrews ⁶, Katie Stewart ⁷, C. Egla Rabinovich ⁸, Robert Fuhlbrigge ⁹, Thomas Mason ¹⁰, Elena Pope ¹¹, Maria Ibarra ¹², Fatma Dedeoglu ¹³, Gloria Higgins ¹⁴, Ronald Laxer ¹⁵, Marilynn Punaro ¹⁶ and Kathryn Torok ¹⁷ for the CARRA investigators, ¹Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, ³University of Iowa Stead Family Children's Hospital, Iowa City, ⁴University of Iowa Carver College of Medicine, Iowa City, ⁵Hackensack Univesity Medical Center, Hackensack, ⁶Rutgers University, Newark, ⁷UT Southwestern, Dallas, ⁸Duke University Hospital, Durham, ⁹University of Colorado, Aurora, ¹⁰Rochester, ¹¹Hospital For Sick Kids, Toronto, Canada, ¹²Children's Mercy Kansas City, Kansas City, ¹³Boston Children's Hospital, Boston, ¹⁴Nationwide Childrens Hospital/ The Ohio State University, Columbus, ¹⁵The Hospital for Sick Children and University of Toronto, Toronto, Canada, ¹⁶Dallas, Texas, ¹⁷Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh
Background/Purpose: Juvenile localized scleroderma (jLS) is a chronic inflammatory and fibrosing disease. Treatment is directed towards controlling disease activity to minimize risk for functional impairment…
Abstract Number: 128 • 2020 Pediatric Rheumatology Symposium
Predictors of Moderate/High Disease Activity in Childhood-Onset Systemic Lupus Erythematosus
Emily Smitherman¹, Rouba Chahine ¹, Timothy Beukelman ¹, Andrea Knight ², AKM Fazlur Rahman ¹, Mary Beth Son ³, Jeffrey R Curtis ⁴ and Aimee Hersh ⁵ for the CARRA investigators, ¹University of Alabama at Birmingham, Birmingham, ²SickKids Research Institute, Toronto, Canada, ³Boston Children's Hospital, Boston, Massachusetts, ⁴University of Alabama at Birmingham, Hoover, ⁵University of Utah Primary Children's Hospital, Salt Lake City
Background/Purpose: Substantial risk of early morbidity and mortality exists for patients with childhood-onset systemic lupus erythematosus (cSLE), but there are limited studies identifying predictors of…
Abstract Number: 139 • 2020 Pediatric Rheumatology Symposium
Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study
Mia Glerup¹, Ellen D Arnstad ², Veronika Rypdal ³, Suvi Peltoniemi ⁴, Kristiina Aalto ⁵, Marite Rygg ⁶, Susan Nielsen ⁷, Anders Fasth ⁸, Lillemor Berntson ⁹, Ellen Nordal ³ and Troels Herlin ¹⁰, ¹Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ²Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, and Department of Pediatrics, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Tromheim, Norway, ³Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, ⁴Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., Helsinki, Finland, ⁵Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, ⁶Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology and Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway., Trondheim, Norway, ⁷Department of Pediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Copenhagen, Denmark, ⁸Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, ⁹Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, ¹⁰Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark
Background/Purpose: Previously, we showed that ILAR JIA categories defined at disease onset change considerably during the first 8 years of disease course. Whether achieved remission…
Abstract Number: L17 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial
Eric Morand¹, Richard Furie ², Yoshiya Tanaka ³, Ian Bruce ⁴, Anca Askanase ⁵, Christophe Richez ⁶, Sang-Cheol Bae ⁷, Philip Brohawn ⁸, Lilia Pineda ⁹, Anna Berglind ¹⁰ and Raj Tummala ⁹, ¹Monash University, Melbourne, Victoria, Australia, ²Zucker School of Medicine at Hofstra/Northwell, New York, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ⁵Columbia University, New York, ⁶CHU de Bordeaux-GH Pellegrin, Bordeaux, France, ⁷Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁸Former employee of AstraZeneca, Gaithersburg, Maryland, ⁹AstraZeneca, Gaithersburg, Maryland, ¹⁰AstraZeneca, Gothenburg, Sweden
Background/Purpose: Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2 study in patients with…
Abstract Number: 1193 • 2019 ACR/ARP Annual Meeting
EMR-integrated Disease Activity Calculators Improve Treatment to Target in Rheumatoid Arthritis
Gabrielle Barbera¹, Jasleen Kahlon ², Manank Patel ³, Scott Pompa ⁴ and Arundathi Jayatilleke ¹, ¹Drexel, Philadelphia, PA, ²Hahnemann, Philadelphia, PA, ³Rutgers, New Brunswick, NJ, ⁴Dartmouth, Lebanon, NH
Background/Purpose: Undertreatment of RA can lead to cumulative joint damage as well as negatively impact emotional health. Recent evidence favors a treat-to-target strategy to achieve…
Abstract Number: 2443 • 2019 ACR/ARP Annual Meeting
A Gender-based Analysis of Disease Activity and Its Relationship with Anxiety, Depression, Fatigue, and Fibromyalgia in Psoriatic Arthritis
Mehmet Tuncay Duruoz¹, Halise Hande Gezer ², Kemal Nas ³, Erkan Kilic ⁴, Betul Sargin ⁵, Sevtap Acer Kasman ¹, Hakan Alkan ⁶, Nilay Sahin ⁷, Gizem Cengiz ⁸, Nihan Cuzdan ⁹, Ilknur Albayrak Gezer ¹⁰, Dilek Keskin ¹¹, Cevriye Mulkoglu ¹², Hatice Resorlu ¹³, Şebnem Ataman ¹⁴, Ajda Bal ¹⁵, Okan Kucukakkas ¹⁶, Ozan Volkan Yurdakul ¹⁶, Meltem Alkan Melikoglu ¹⁷, Yildiray Aydin ³, Fikriye Figen Ayhan ¹⁸, Hatice Bodur ¹⁹, Mustafa Calis ⁸, Erhan Capkin ²⁰, Gul Devrimsel ²¹, Kevser Gök ²², Sami Hizmetli ²³, Ayhan Kamanli ³, Yasar Keskin ¹⁶, Hilal Kocabas ²⁴, Oznur Kutluk ²⁵, Nesrin Sen ²⁶, Omer Faruk Sendur ²⁷, Ibrahim Tekeoglu ³, Sena Tolu ²⁸, Murat Toprak ²⁹ and Tiraje Tuncer ²⁵, ¹Marmara University School of Medicine, PMR Department, Rheumatology Division, İstanbul, Turkey, ²Marmara University School of Medicine, PMR Department, Rheumatology Division, İstanbul, Istanbul, Turkey, ³Sakarya University School of Medicine, PMR Department, Rheumatology and Immunology Division, Sakarya, Turkey, ⁴Afyonkarahisar State Hospital, Afyonkarahisar, Turkey, ⁵Adnan Menderes University School of Medicine, PMR Department, Rheumatology Division, Aydın, Turkey, ⁶Pamukkale University School of Medicine, PMR Department, Rheumatology Division, Denizli, Turkey, ⁷Balıkesir University School of Medicine, PMR Department, Balıkesir, Turkey, ⁸Erciyes University School of Medicine, PMR Department, Rheumatology Division, Kayseri, Turkey, ⁹Şanlıurfa Training and Research Hospital, Rheumatology Clinic, Şanlıurfa, Turkey, ¹⁰Selçuk University School of Medicine, PMR Department, Konya, Turkey, ¹¹Kırıkkale University School of Medicine, PMR Department, Kırıkkale, Turkey, ¹²Ankara Training and Research Hospital, PMR Clinic, Ankara, Turkey, ¹³Çanakkale Onsekiz Mart University School of Medicine, PMR Department, Çanakkale, Turkey, ¹⁴Ankara University School of Medicine, Physical Medicine and Rehabilitation, Rheumatology Department, Ankara, Ankara, Turkey, ¹⁵Dışkapı Yıldırım Beyazıt Training and Research Hospital, PMR Clinic, Ankara, Turkey, ¹⁶Bezmialem Vakıf University School of Medicine, PMR Department, İstanbul, Turkey, ¹⁷Atatürk University School of Medicine, PMR Department, Rheumatology Division, Erzurum, Turkey, ¹⁸Uşak University School of Health Sciences, PMR Department, Uşak, Turkey, ¹⁹Yıldırım Beyazıt University School of Medicine, PMR Department, Ankara, Turkey, ²⁰Karadeniz Teknik University School of Medicine, PMR Department, Trabzon, Turkey, ²¹Recep Tayyip Erdoğan University School of Medicine, PMR Department, Riza, Turkey, ²²Numune Training and Research Hospital, Rheumatology Clinic, Ankara, Turkey, ²³Cumhuriyet University School of Medicine, PMR Department, Rheumatology Division, Sivas, Turkey, ²⁴Necmettin Erbakan University Meram School of Medicine, PMR Department, Rheumatology Division, Konya, Turkey, ²⁵Akdeniz University School of Medicine, PMR Department, Rheumatology Division, Antalya, Turkey, ²⁶Kartal Dr. Lütfi Kırdar Training and Research Hospital, Rheumatology Clinic, İstanbul, Turkey, ²⁷Adnan Menderes University School of Medicine, PMR Department, Aydın, Turkey, ²⁸Medipol University School of Medicine, PMR Department, İstanbul, Turkey, ²⁹Yüzüncü Yıl University School of Medicine, PMR Department, Van, Turkey
Background/Purpose: This study sought to compare the disease activity and its relationship with anxiety, depression, fatigue, and fibromyalgia of patients with psoriatic arthritis (PsA) between…
Abstract Number: 36 • 2019 ACR/ARP Annual Meeting
Discovery, Verification and Validation of Rheumatoid Arthritis Activity Monitoring Biomarkers
Lucía González-Rodríguez¹, Valentina Calamia ¹, Rocío Paz-González ¹, Patricia Fernández-Puente ¹, Cristina Ruiz-Romero ¹, Antonio Julià ², Antonio Fernández-Nebro ³, Jesús Tornero ⁴, Sara Marsal ⁵ and Francisco J. Blanco ⁶, ¹Proteomics Group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña,15006 A Coruña-Spain, A Coruña, Galicia, Spain, ²Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Catalonia, Spain, ³UGC Reumatología, Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Spain., Málaga, Andalucia, Spain, ⁴Hospital Universitario Guadalajara, Guadalajara, Spain., Guadalajara, Castilla-La Mancha, Spain, ⁵Vall d’Hebron Hospital, Barcelona, Catalonia, Spain, ⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a long-lasting inflammatory autoimmune disorder that ultimately leads to the destruction of joint architecture. The activity of this disease is…
Abstract Number: 1355 • 2019 ACR/ARP Annual Meeting
A Comparison of Clinical Improvement Following a Major Therapeutic Change Utilizing Updated Treatment Thresholds Defined by Three Different Disease Activity Measures
Grant Cannon¹, Wei Chen ¹, JIncheng Shen ², Neil Accortt ³, David Collier ⁴ and Brian Sauer ¹, ¹Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, ²Univeristy of Utah, Salt Lake City, UT, ³Amgen, Thousand Oaks, CA, ⁴Amgen Inc., Thousand Oaks, CA
Background/Purpose: Despite ACR recommendations to initiate a major therapeutic change (MTC) in rheumatoid arthritis (RA) patients with moderate/severe disease activity, our recent work has shown…
Abstract Number: 2483 • 2019 ACR/ARP Annual Meeting
Comparison Between Composite Activity Indices to Assess Clinical Response to Biological Therapy in Patients with Psoriatic Arthritis
Diego Benavent¹, Chamaida Plasencia ², Victoria Navarro-Compán ³, Diana Peiteado ⁴, Laura Nuño ⁵, Irene Monjo ⁶, Elisa Fernández ⁷ and Alejandro Balsa ², ¹Hospital Universitario La Paz, Madrid, Spain, ²Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, ³University Hospital La Paz, IdiPaz, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, ⁵Immuno-Rheumatology research group , Institute for Health Research (IdiPAZ), Madrid, Spain, MADRID, Spain, ⁶FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, ⁷Rheumatology Department, La Paz University Hospital, Madrid, Madrid, Spain
Background/Purpose: Assessment of the disease in psoriatic arthritis (PsA) remains a clinical challenge. Hence, there is no agreement on which index best correlates with the…
Abstract Number: 46 • 2019 ACR/ARP Annual Meeting
Key Inflammatory Biomarkers at Baseline Are Associated with Filgotinib Response at Week 12 in Rheumatoid Arthritis Patients with Inadequate Response or Intolerance to Biologic DMARDs
Peter Taylor¹, Emon Elboudwarej ², Bryan Downie ³, Rachael Hawtin ², Jinfeng Liu ² and Amer M. Mirza ², ¹University of Oxford, Oxford, United Kingdom, ²Gilead Sciences, Inc., Foster City, CA, ³Gilead Sciences, Inc., Foster Citty, CA
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in Phase 3 studies of active RA in patients (pts) with inadequate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].